Denise Peterson

US biopharma editor at IBI Pharma (Pink Sheet and Scrip

[Denise Peterson @PinkSheetDenise]

Time to spotlight folks doing great work in R&D strategy and trial design, including excellence in AI, diversity, RWE, and patient-facing technology. Nominate them for the Citeline Awards; deadline is now March 1. https://t.co/J2VYLKBNQ5

[Mandy Jackson @ScripMandy]

A holiday gift for anyone wondering what I was up to for @PharmaScrip at #ASH24 a few weeks ago: one of my long reads about what’s happening in sickle cell disease is free to read without a subscription. https://t.co/uIGf4gbDxl

[Sue Sutter @PinkSheetSutter]

@PharmaPinkSheet previously reported on sponsor's plans to contest withdrawal - get caught up here https://t.co/k6PxQlBTkY

[Denise Peterson @PinkSheetDenise]

My comrade Brenda Sandburg several years ago profiled pioneering photojournalist Betty Steele, who died recently. Here’s an short – and wonderful – clip of Brenda interviewing Betty. Inspiring.

[Brenda Sandburg @brendasandburg]

https://t.co/bns7MmA5D6 This clip shows some of Betty's amazing photos.

[KFF Health News @KFFHealthNews]

Join host @jrovner and panelists @shefalil, @SarahKarlin, and @AliceOllstein for a new health-packed ep. of #WTHealth! This week's discussion includes reproductive health, drug pricing, legislation for organ transplants, and more! https://t.co/kX5Lslmet0

[Denise Peterson @PinkSheetDenise]

My TrialScope colleagues are benchmarking how biopharmas balance clinical trial reporting compliance/transparency with redacting sensitive company & patient data. If you’re involved in this area, help us out by taking this brief confidential survey: https://t.co/Y1dRmzmXzI

[Sarah Karlin-Smith @SarahKarlin]

More on the House Republican drug shortage bill this came from, from me last week: https://t.co/L8lZWQ0g8F

[Denise Peterson @PinkSheetDenise]

Thomas Wicks, a Citeline colleague & trial transparency SME, is benchmarking how pharma is balancing transparency with needs to redact or anonymize some data. Help us out with our survey. #clinicaltrials #redaction #transparency
https://t.co/u8H5n9BVU3

[Sue Sutter @PinkSheetSutter]

A handy, quick reference for tracking industry lawsuits over the IRA's drug price negotiation provisions https://t.co/hTtSeIbEUV

[Vibha Sharma @ScripRegVibha]

Saudi FDA’s membership to PIC/s means that it can become a reference authority for inspecting pharmaceutical factories, reports @ScripFrancesca

https://t.co/oRm8Vuyb4x

[Sue Sutter @PinkSheetSutter]

Wow - only 6 voting members on panel, 2 of whom are regular members of the PCNSDAC. In all my many many years of covering adcomms have never seen a panel that small.

[Sarah Karlin-Smith @SarahKarlin]

Our first day #BIO2023 notefrom from me, @ScripMandy and Kevin Grogan.

https://t.co/8c8PXVRlr8

[Denise Peterson @PinkSheetDenise]

@VikasReports @BioPharmaJosh love this!

[Derrick @dgingery]

(2/2) And here is @PinkSheetSutter's look at Pepaxto from the FDA perspective ... #PinkSheet #pharma: https://t.co/1iKZmCxn3y

[Derrick @dgingery]

(1/2) An interesting look at the saga of Pepaxto from our @ScripFrancesca and @PinkSheetSutter today. This is Francesca's look at the EMA perspective ... #pinksheet #pharma: Oncopeptides’ Melflufen: Same Data, Different Conclusions From EMA, US FDA https://t.co/7pv87M3jJU

[Derrick @dgingery]

More supplemental filings from me and @SarahKarlin ... #pinksheet #pharma: Supplemental Filings: Pink Sheet Notebook On Disease Lobbying, Dan Leonard’s Next Act, And More https://t.co/4vGvoA0u6v

[Sue Sutter @PinkSheetSutter]

Our quick hit on the Makena situation
https://t.co/0q4iVq3hKU

[Derrick @dgingery]

Our take on yesterday's big neurology news from @PinkSheetSutter ... #pinksheet #pharma: @US_FDA Neuroscience Office Director Billy Dunn Departs As Agency Faces New Review Challenges https://t.co/7ucRnd3ZZW

[Derrick @dgingery]

My analysis of the new OPT org chart ... #Pinksheet #Pharma: CBER’s New Home For Gene Therapies: OTAT Changes To OTP But Leadership Questions Remain https://t.co/wnzsf6qGS7

[Sue Sutter @PinkSheetSutter]

“We have these big societal issues and the decision about an individual product is like the tip of the spear of something that needs context,” @US_FDA's Robert Califf says about use of adcomms @SarahKarlin https://t.co/4pyOAlNgFD